MADRIGAL PHARMA Revenue, Profits - MDGL Annual Income Statement

Add to My Stocks
$215.76 $8.46 (4.08%) MDGL stock closing price Sep 19, 2018 (Closing)

Looking at financial statements, along with the MADRIGAL PHARMA stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2017 impacts the MDGL stock. Investors typically check year over year or quarter over quarter revenue growth. The MADRIGAL PHARMA profit and loss statement for 2017 shows a net profit of $-31.15M. Profits for last year was $-26.38M. Apart from this an investor should also check MADRIGAL PHARMA assets and MADRIGAL PHARMA free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
MADRIGAL PHARMA Revenues or Net Sales
Cost Of Goods Sold (COGS)----------
Research & Development Expense24.39M15.93M54.21M68.2M71.86M49.41M41.46M40.25M51.05M81.58M
Selling General & Admin Expense7.67M9.29M13.39M15.74M15.69M11.67M11.55M11.44M13.88M14.74M
Income Before Depreciation Depletion Amortization-32.06M-25.22M-67.61M-83.95M-87.55M-60.94M-45.43M-36.89M79.3M-93.7M
Depreciation Depletion Amortization----------
Non Operating Income--------0.56M-1.57M
Interest Expense-1.21M1.06M2.21M2.63M1.84M1.94M---
Provision for Income Taxes----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-31.15M-26.38M-68.67M-86.16M-90.19M-62.79M-47.38M-37.46M79.08M-92.61M
Extraordinary Items & Discontinued Operations----------
MADRIGAL PHARMA Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS12.25M5.21M3.68M2.82M2.03M1.7M1.35M1.15M--
Average Shares used to compute Basic EPS12.25M5.21M3.68M2.82M2.03M1.7M1.35M1.15M--
Income Before Nonrecurring Items-31.15M-26.39M-68.67M-86.16M-90.19M-62.79M-47.38M-37.47M79.9M-92.62M
Income from Nonrecurring Items---------0.82M-
MADRIGAL PHARMA Earnings Per Share Basic Net
MADRIGAL PHARMA Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-2.54-5.07-18.53-30.42-44.41-37.06-34.97-32.5281.82-96.15
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on MADRIGAL PHARMA stock analysis. It helps to look at the following income statement items:

  • Topline: A growing topline, as seen from the MADRIGAL PHARMA revenue chart, as isn't the case with MADRIGAL PHARMA indicates a sagging business. One needs to compare the YoY topline or sales growth of MDGL stock with its peers like TARO stock and EVTCY stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-31.15M for MADRIGAL PHARMA for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the MDGL income statement, one can check the MADRIGAL PHARMA historical stock prices to check how the price has moved with time.

MADRIGAL PHARMA Income Statement - Key Financial Ratios

Operating Margin
Net Profit Margin